Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D H Lau

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Journal of the National Cancer Institute|October 21, 1992
Characterization of covalent DNA binding of morpholino and cyanomorpholino derivatives of doxorubicinD H Lau, G E Durán, B I Sikic
Clinical Pharmacology and Therapeutics|January 1, 1977
Plasma l-alpha-Acetylmethadol (LAAM) after acute and chronic administrationG L Henderson, B K Wilson, D H Lau
Cancer Research|July 1, 1990
Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicinD H Lau, K L Ross, B I Sikic
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|August 1, 1997
Clonal origin of multiple lung cancers: K-ras and p53 mutations determined by nonradioisotopic single-strand conformation polymorphism analysisD H Lau, B Yang, R Hu, et al.
Seminars in Oncology|July 7, 2001
Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non--small cell lung cancer: focus on docetaxelD R Gandara, P N Lara, Z Goldberg, et al.
Oncology (Williston Park, N.Y.)|August 29, 2000
Gemcitabine/carboplatin combination regimens: importance of dose scheduleD R Gandara, D H Lau, P N Lara, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Sensitization of drug resistant human ovarian cancer cells to cyanomorpholino doxorubicin (MRA-CN) by modulation of glutathione metabolismA D Lewis, G E Durán, D H Lau, et al.
International Journal of Radiation Oncology, Biology, Physics|April 1, 1997
Concurrent carboplatin, etoposide and thoracic radiation for poor-risk stage III non-small-cell lung carcinoma: a pilot studyD H Lau, J K Ryu, D R Gandara, et al.
Oncology (Williston Park, N.Y.)|April 17, 2001
Gemcitabine in combination with new platinum compounds: an updateD R Gandara, M J Edelman, P N Lara, et al.
British Journal of Cancer|July 1, 1994
Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linkerD H Lau, G E Duran, A D Lewis, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Journal of the National Cancer Institute|October 21, 1992
Characterization of covalent DNA binding of morpholino and cyanomorpholino derivatives of doxorubicinD H Lau, G E Durán, B I Sikic
Clinical Pharmacology and Therapeutics|January 1, 1977
Plasma l-alpha-Acetylmethadol (LAAM) after acute and chronic administrationG L Henderson, B K Wilson, D H Lau
Cancer Research|July 1, 1990
Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicinD H Lau, K L Ross, B I Sikic
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|August 1, 1997
Clonal origin of multiple lung cancers: K-ras and p53 mutations determined by nonradioisotopic single-strand conformation polymorphism analysisD H Lau, B Yang, R Hu, et al.
Seminars in Oncology|July 7, 2001
Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non--small cell lung cancer: focus on docetaxelD R Gandara, P N Lara, Z Goldberg, et al.
Oncology (Williston Park, N.Y.)|August 29, 2000
Gemcitabine/carboplatin combination regimens: importance of dose scheduleD R Gandara, D H Lau, P N Lara, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Sensitization of drug resistant human ovarian cancer cells to cyanomorpholino doxorubicin (MRA-CN) by modulation of glutathione metabolismA D Lewis, G E Durán, D H Lau, et al.
International Journal of Radiation Oncology, Biology, Physics|April 1, 1997
Concurrent carboplatin, etoposide and thoracic radiation for poor-risk stage III non-small-cell lung carcinoma: a pilot studyD H Lau, J K Ryu, D R Gandara, et al.
Oncology (Williston Park, N.Y.)|April 17, 2001
Gemcitabine in combination with new platinum compounds: an updateD R Gandara, M J Edelman, P N Lara, et al.
British Journal of Cancer|July 1, 1994
Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linkerD H Lau, G E Duran, A D Lewis, et al.
Pageof 5